5 Grants
2021
Targeting NQO1+ tumor to trigger innate and adaptive immunity
Huang, Xiumei
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA240952-02), $407,082USD, 2020-07-13 -- 2025-06-30
 
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs
Huang, Xiumei
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA224493-04), $342,266USD, 2018-01-10 -- 2022-12-31
 
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
Huang, Xiumei and Motea, Edward A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA221158-05), $362,731USD, 2017-06-07 -- 2022-11-30
2020
Targeting NQO1+ tumor to trigger innate and adaptive immunity
Huang, Xiumei
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA240952-01A1), $421,360USD, 2020-07-13 -- 2025-06-30
 
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs
Huang, Xiumei
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA224493-03), $360,281USD, 2018-01-10 -- 2022-12-31